BMS gets FDA approval for Opdivo plus Yervoy to treat HCC
Bristol Myers Squibb Company announced that Opdivo (nivolumab) 1 mg/kg plus Yervoy (ipilimumab) 3 mg/kg (injections for intravenous use) was approved by the U.S. Food and Drug…
Read More...
Read More...
